Skip to content

The effect of Valsartan and Amlodipine combination with two different forms in controlling 24-hour ambulatory blood presure

Comparison of the effect of Valsartan 80mg and Amlodipine 5mg as combination fix dose therapy and combination free drug therapy in controlling 24-hour ambulatory blood pressure

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221016056199N1
Enrollment
136
Registered
2022-12-11
Start date
2022-12-22
Completion date
Unknown
Last updated
2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension. Essential (primary) hypertension

Interventions

Intervention 1: Intervention group 1: In this group, 68 patients randomly undergo 24-hour ambulatory blood pressure monitoring with blood pressure holter and then combination fix dose of Valsartan 80m

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 70 Years

Inclusion criteria

Inclusion criteria: New case of hypertension stage 1 or 2 hypertension

Exclusion criteria

Exclusion criteria: Severe hypertension Secondary hypertension Positive history of ischemic heart disease Patients on anti-hypertensive drugs beforehand Patients who are not volunteered

Design outcomes

Primary

MeasureTime frame
Average 24-hour systolic and diastolic blood pressure. Timepoint: At the beginning of the study and 60 days after starting treatment. Method of measurement: Holter monitoring of blood pressure.;Mean arterial pressure. Timepoint: At the beginning of the study and 60 days after starting treatment. Method of measurement: Holter monitoring of blood pressure.

Secondary

MeasureTime frame
Average daytime systolic and diastolic blood pressure. Timepoint: At the beginning of the study and 60 days after starting treatment. Method of measurement: Holter monitoring of blood pressure.;Average nighttime systolic and diastolic blood pressure. Timepoint: At the beginning of the study and 60 days after starting treatment. Method of measurement: Holter monitoring of blood pressure.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKimia Falamarzi

Shiraz University of Medical Sciences

kimiafalamarzi@yahoo.com+98 71 3646 3245

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026